Business
Ngenla (somatrogon: Pfizer) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Key opportunities in the market include the rising demand for long-acting growth hormone therapies, expanding biologics manufacturing, and improved patient adherence. Asia-Pacific presents the fastest growth potential, with personalized endocrine care and localized production offering strategic advantages.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Ngenla Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The
About this update from Pfizer, Inc.
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g_3H8YP5.WdAX5cBtX03VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"Key opportunities in the market include the rising demand for long-acting growth hormone therapies, expanding biologics manufacturing, and improved patient adherence. Asia-Pacific presents the fastest growth potential, with personalized endocrine care and localized production offering strategic advantages.","length":307,"tagName":"p"},{"type":"text","content":"Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Ngenla Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.","length":208,"tagName":"p"},{"type":"text","content":"The Ngenla market, driven by the increasing diagnosis of growth hormone deficiency (GHD), is poised for substantial growth. Historic growth stems from improved diagnostic rates, the established daily use of somatropin therapies, advancements in recombinant DNA technology, and heightened awareness in pediatric endocrinology. The forecast period anticipates rising demand for long-acting endocrine therapies and increased adult GHD diagnosis rates, alongside a focus on quality-of-life outcomes and expanded biologics manufacturing capacity.","length":541,"tagName":"p"},{"type":"text","content":"Ngenla, a long-acting recombinant human growth hormone (somatrogon), responds to these needs by providing sustained hormone release through once-weekly injections. This significantly reduces the burden of daily treatment, enhances adherence, and promotes growth in children with GHD. According to the National Library of Medicine, pediatric GHD affects 1 in 3,500 to 1 in 10,000 children, which underscores the growing market potential for Ngenla as its prevalence increases.","length":475,"tagName":"p"},{"type":"text","content":"The market is characterized by its focus on long-acting therapies, aimed at improving adherence and ou...